PMID- 10623701
OWN - NLM
STAT- MEDLINE
DCOM- 20000217
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 18
IP  - 1
DP  - 2000 Jan
TI  - Differential expression of nuclear retinoid receptors in normal and malignant 
      prostates.
PG  - 116-21
AB  - PURPOSE: To determine (1) whether nuclear retinoic acid receptors (RARs) and 
      retinoid X receptors (RXRs) are differentially expressed in normal and in 
      cancerous human prostate tissues and (2) whether oral fenretinide therapy impacts 
      the expression of these receptors in prostate cancer. PATIENTS AND METHODS: In 
      situ hybridization with antisense riboprobes was used to probe for RAR and RXR 
      transcripts in prostate tissues in a two-phased study: (1) expression of retinoid 
      receptors in eight normal prostates was compared with their expression in 10 
      randomly picked radical prostatectomy specimens (group A); (2) expression of 
      retinoid receptors was determined in 22 radical prostatectomy specimens from 
      participants in a clinical study (group B). Twelve patients received oral 
      fenretinide 200 mg/d, and 10 received placebo pills for 28 days before surgery. 
      RESULTS: RARalpha, RARgamma, RXRalpha, and RXRgamma mRNAs were detected in most 
      normal and cancerous prostates. In group A, RARbeta mRNA was expressed in only 
      four of 10 malignant prostates but was present in seven of eight benign prostates 
      (P =.05). RXRbeta mRNA was expressed in four of eight benign prostates and in 
      zero of 10 malignant prostates (P =.023). In group B prostates, RARbeta and 
      RXRbeta mRNAs were markedly reduced in all cancers and in the adjacent, 
      nonmalignant tissue. There were no differences between receptor expression in the 
      fenretinide-treated group and the placebo group. CONCLUSION: RARbeta and RXRbeta 
      mRNAs are selectively lost in both prostate cancer and adjacent morphologically 
      normal prostatic tissue, supporting the concept of a field of carcinogenesis. One 
      month of oral fenretinide (200 mg/d) did not influence the expression of retinoid 
      receptors in prostate cancer.
FAU - Lotan, Y
AU  - Lotan Y
AD  - Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA.
FAU - Xu, X C
AU  - Xu XC
FAU - Shalev, M
AU  - Shalev M
FAU - Lotan, R
AU  - Lotan R
FAU - Williams, R
AU  - Williams R
FAU - Wheeler, T M
AU  - Wheeler TM
FAU - Thompson, T C
AU  - Thompson TC
FAU - Kadmon, D
AU  - Kadmon D
LA  - eng
GR  - P50-58204/PHS HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Transcription Factors)
RN  - 187EJ7QEXL (Fenretinide)
SB  - IM
MH  - Aged
MH  - Anticarcinogenic Agents/pharmacology
MH  - Fenretinide/pharmacology
MH  - Humans
MH  - In Situ Hybridization
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/drug effects/genetics/*metabolism
MH  - Prostate/cytology/*metabolism
MH  - Prostatic Neoplasms/genetics/*metabolism/prevention & control
MH  - Receptors, Retinoic Acid/drug effects/genetics/*metabolism
MH  - Transcription Factors/drug effects/genetics/*metabolism
EDAT- 2000/01/07 09:00
MHDA- 2000/02/19 09:00
CRDT- 2000/01/07 09:00
PHST- 2000/01/07 09:00 [pubmed]
PHST- 2000/02/19 09:00 [medline]
PHST- 2000/01/07 09:00 [entrez]
AID - 10.1200/JCO.2000.18.1.116 [doi]
PST - ppublish
SO  - J Clin Oncol. 2000 Jan;18(1):116-21. doi: 10.1200/JCO.2000.18.1.116.